Details of the Drug Combinations

General Information of This Drug (ID: DMKSUOI)

• Drug Name: Flavopiridol (DMKSUOI)
• Synonyms: FLAVO; Alvocidib [INN]; Flavopiridol hydrochloride; L 868275; HMR-1275; L-868275; L86-8275; HMR-1275, Alvocidib, L868275, Flavopiridol; (-)-cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one; 2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE; 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one

Indication

Acute myeloid leukaemia; ICD 11: 2A60; Status: Phase 2 [1]; Chronic lymphocytic leukaemia; ICD 11: 2A82.0; Status: Discontinued in Phase 3 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

18 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
AS602868 + Flavopiridol	DCA05T8	AS602868	Glioblastoma (Cell Line: JHH-136)	[3]
CA4P + Flavopiridol	DCS4BQR	CA4P	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
Doxorubicin + Flavopiridol	DC7V6U8	Doxorubicin	Glioblastoma (Cell Line: JHH-136)	[3]
Flavopiridol + Ruxolitinib	DCNXIFM	Ruxolitinib	T-cell leukemia/lymphoma (Cell Line: ED-40515)	[3]
Flavopiridol + Trametinib	DCX9BN2	Trametinib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
Flavopiridol + JQ1	DC0KNR8	JQ1	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
Flavopiridol + TAK-733	DCVESIK	TAK-733	Glioblastoma (Cell Line: JHH-136)	[3]
Flavopiridol + THAPSIGARGIN	DCU7OTF	THAPSIGARGIN	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
Flavopiridol + Marizomib	DCC0PHV	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[3]
Flavopiridol + Mitomycin	DCO79WP	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[3]
Flavopiridol + BMS-754807	DCV0VZG	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
Flavopiridol + KU-0060648	DCZ21M9	KU-0060648	Diffuse large B cell lymphoma (Cell Line: TMD8)	[3]
Flavopiridol + PF-04691502	DCBGPJY	PF-04691502	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
Flavopiridol + PF-562271	DCYZEU4	PF-562271	Diffuse large B cell lymphoma (Cell Line: TMD8)	[3]
Flavopiridol + Ibrutinib	DCEC7I3	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[3]
Plinabulin + Flavopiridol	DCF621M	Plinabulin	Glioblastoma (Cell Line: JHH-136)	[3]
Topetecan + Flavopiridol	DCQ7846	Topetecan	Glioblastoma (Cell Line: JHH-136)	[3]
Vorinostat + Flavopiridol	DCQE8MP	Vorinostat	Glioblastoma (Cell Line: JHH-136)	[3]

12 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Docetaxel + Flavopiridol	DC0KSVQ	Docetaxel	Adenocarcinoma of the Pancreas	[4]
Flavopiridol + Irinotecan	DC4XMO9	Irinotecan	Adenocarcinoma of the Gastroesophageal Junction	[5]
Flavopiridol + Vorinostat	DCCZNIU	Vorinostat	Blastic Phase Chronic Myelogenous Leukemia	[6]
Flavopiridol + Vorinostat	DCH0OLQ	Vorinostat	Unspecified Adult Solid Tumor, Protocol Specific	[7]
Flavopiridol + Fludarabine	DCPJKXG	Fludarabine	B-cell Chronic Lymphocytic Leukemia	[8]
Flavopiridol + Mitoxantrone	DCPHSFU	Mitoxantrone	Adult Acute Megakaryoblastic Leukemia (M7)	[9]
Flavopiridol + Daunorubicin	DCPZJ07	Daunorubicin	Acute Myeloid Leukemia	[10]
Flavopiridol + Mitoxantrone	DCXLGKE	Mitoxantrone	Recurrent Adult Acute Lymphoblastic Leukemia	[11]
Venetoclax + Flavopiridol	DCF4LAK	Venetoclax	Acute Myeloid Leukemia (AML)	[12]
Flavopiridol + Mitoxantrone	DC2VD8I	Mitoxantrone	Adult Acute Basophilic Leukemia	[13]
Flavopiridol + Mitoxantrone	DC8MWRX	Mitoxantrone	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome	[14]
Flavopiridol + Mitoxantrone	DCX5ANI	Mitoxantrone	Acute Myeloid Leukemia	[15]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5680).
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT00331682) Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
• [5] ClinicalTrials.gov (NCT00991952) Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
• [6] ClinicalTrials.gov (NCT00278330) Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
• [7] ClinicalTrials.gov (NCT00324480) Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
• [8] ClinicalTrials.gov (NCT00058227) Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
• [9] ClinicalTrials.gov (NCT00470197) Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
• [10] ClinicalTrials.gov (NCT03298984) Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
• [11] ClinicalTrials.gov (NCT00016016) Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia
• [12] ClinicalTrials.gov (NCT03441555) A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
• [13] ClinicalTrials.gov (NCT00407966) Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
• [14] ClinicalTrials.gov (NCT00795002) Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
• [15] ClinicalTrials.gov (NCT02520011) Alvocidib Biomarker-driven Phase 2 AML Study